What is Qlaris Bio?
Qlaris Bio is a clinical-stage biotechnology firm focused on pioneering first-in-class treatments for serious eye conditions, with a particular emphasis on glaucoma. The company's lead candidate, QLS-111, is designed to manage intraocular pressure through a distinct mechanism, potentially offering an advantage over current therapeutic options. Qlaris Bio is committed to addressing critical unmet needs in ophthalmology, aiming to preserve vision and prevent blindness for patients affected by conditions such as Primary Open-Angle Glaucoma and Ocular Hypertension.
How much funding has Qlaris Bio raised?
Qlaris Bio has raised a total of $24M across 1 funding round:
Series B
$24M
Series B (2024): $24M with participation from New Leaf Venture Partners and Canaan
Key Investors in Qlaris Bio
New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm dedicated to supporting innovative companies within the healthcare sector, aiming to drive advancements that improve patient outcomes.
Canaan
Canaan Inc. is a technology company known for its high-performance computing chips and mining equipment, though in this context, it likely represents their venture capital arm's interest in biotechnology.
What's next for Qlaris Bio?
The recent major enterprise-level funding indicates Qlaris Bio is likely in a scaling phase, poised to advance its lead candidate through further clinical trials and potentially prepare for commercialization. This strategic investment will be crucial for expanding its research and development capabilities, navigating regulatory pathways, and solidifying its market position in the competitive ophthalmology sector. The company's focus on innovative mechanisms for treating glaucoma suggests a long-term vision for transforming patient care.
See full Qlaris Bio company page
